reports
u-blox shareholders approve all motions proposed by the Board of Direc...
u-blox AG / Key word(s): AGMEGM u-blox shareholders approve all motions proposed by the Board of Directors at the Ordinary General Meeting 2024 19.04.2024 / 07:00 CET/CEST Thalwil, Switzerland – 19 April 2024 – u-blox (SIX: UBXN), a global provider of leading positioning and wireless communication technologies and services, announces that shareholders approved all motions proposed by the Board of Directors at today’s Ordinary Annual General Meeting 2024, held in Horgen. Shareholders re-elected André Müller as Chairman of the Board of Directors. Ulrich Looser, Markus Borchert, Kari...
Nyrstar NV 2023 Full Year Results
Nyrstar NV 2023 Full Year Results Regulated Information Nyrstar NV 2023 Full Year Results 19 April 2024 at 07:00 CEST Nyrstar NV ("Nyrstar" or the “Company”) is today announcing the publication of its financial statements for the twelve months ended 31 December 2023 (“Full Year Results 2023”). The Full Year Results 2023 have been prepared on a discontinuity basis as a result of the decision of the extraordinary shareholders’ meeting of 9 December 2019 to reject the continuation of the Company’s activities. The Company has received from its auditor, and is publishing toda...
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line ...
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer OSLO, Norway, April 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced the initiation of the Phase 2 clinical trial VB-C-04. The trial evaluates VB10.16, the company’s off-the-shelf therapeutic cancer vaccine candidate for HPV16-positive cancers, alone or in combination with Roche’s checkpoint inhibitor atezolizumab (Tecentriq®1) in patients with HP...
CONVENING NOTICE TO THE ORDINARY GENERAL MEETINGS OF SHAREHOLDERS
CONVENING NOTICE TO THE ORDINARY GENERAL MEETINGS OF SHAREHOLDERS UNIFIEDPOST GROUP Public limited liability company (“naamloze vennootschap”. / “société anonyme“) under Belgian law Registered office at Avenue Reine Astrid 92A, 1310 La Hulpe, BelgiumCompany number 0886.277.617 Register of Legal Entities Walloon Brabant CONVENING NOTICE TO THE ORDINARY GENERAL MEETINGS OF SHAREHOLDERS The Board of Directors of Unifiedpost Group SA/NV (the Company) has the honour of inviting its shareholders and holders of warrants to attend the ordinary general shareholders' me...
Pluxee delivers strong performance in the First Half and raises Fiscal...
Pluxee delivers strong performance in the First Half and raises Fiscal 2024 Organic revenue growth and Recurring EBITDA margin objectives First Half Fiscal 2024 ResultsIssy-les-Moulineaux, France – April 19, 2024 First Half Fiscal 2024 highlights Successful spin-off and listing on Euronext Paris on February 1, 2024 Organic revenue growth of +24% incl. +26% in Q2, reflecting buoyant performance across all regions Strong Recurring EBITDA at €201 million, i.e. +28% organic growth; 34.4% margin at constant rates Net profit of €68 million reflecting higher one-time items, mostly spin-off rel...
Pluxee affiche une performance solide au premier semestre et relève se...
Pluxee affiche une performance solide au premier semestre et relève ses objectifs de croissance organique du chiffre d’affaires et de marge d’EBITDA récurrent pour l’exercice fiscal 2024 Résultats du premier semestre de l’exercice fiscal 2024Issy-les-Moulineaux, France – 19 avril 2024 Faits marquants du premier semestre de l’exercice 2024 Spin-off et cotation réussis sur Euronext Paris le 1er février 2024 Croissance organique du chiffre d’affaires de +24% dont +26% au deuxième trimestre - reflétant une bonne dynamique pour l’ensemble des régionsSolide EBITDA récurrent att...
Addex to Present at the Swiss Biotech Day 2024
Addex to Present at the Swiss Biotech Day 2024 Geneva, Switzerland, April 19, 2024 - (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the conference taking place April 22 - 23, 2024 at the Congress Center in Basel, Switzerland. In his live presentation, scheduled for 13:45 – 14:00 CEST, on April 23, 2024, in the Samarkand room on the third floor, Mr. Dyer will provide a corporate update and discuss recent developments at Addex. Mr. Dyer will be available fo...
Sodexo announces solid H1 Fiscal 2024 results
Sodexo announces solid H1 Fiscal 2024 results Issy-les-Moulineaux, April 19, 2024 Sodexo (Euronext Paris FR 0000121220-OTC: SDXAY) Sodexo announces solid H1 Fiscal 2024 results Organic Revenue growth +8.5%Underlying operating profit +16.9% at constant currencies, margin up +40 bpsFiscal 2024 guidance: Organic growth now expected at the top of the +6% to +8% rangeUnderlying operating profit margin improvement confirmed at +30 to +40 bps, at constant currencies At the Board of Directors meeting held on April 18, 2024, chaired by Sophie Bellon, the Board closed the Consolidated acc...
Sodexo annonce des résultats solides pour le 1er semestre de l'exercic...
Sodexo annonce des résultats solides pour le 1er semestre de l'exercice 2024 Issy-les-Moulineaux, 19 avril 2024Sodexo (Euronext Paris FR 0000121220-OTC: SDXAY) Sodexo annonce des résultats solides pour le 1er semestre de l'exercice 2024 Croissance interne du chiffre d’affaires de +8,5%Résultat d’exploitation en hausse de +16,9% à taux constants, marge d'exploitation en progression de +40 points de basePerspectives pour l’exercice 2024 : Une croissance interne du chiffre d'affaires désormais attendue en haut de la fourchette de +6% à +8%Une hausse de la marge d’exploitation confirmée en...
Nyrstar NV Jaarresultaten 2023
Nyrstar NV Jaarresultaten 2023 Gereglementeerde Informatie Nyrstar NV Jaarresultaten 2023 19 april 2024 om 07.00 CEST Nyrstar NV ("Nyrstar" of de “Vennootschap”) kondigt vandaag de publicatie van haar jaarrekening aan voor de twaalf maanden afgesloten op 31 december 2023 (“Jaarresultaten 2023”). De Jaarresultaten 2023 werden opgesteld op basis van discontinuïteit als gevolg van de beslissing van de buitengewone algemene vergadering van 9 december 2019 om de voortzetting van de activiteiten van de Vennootschap te verwerpen. De Vennootschap heeft van haar commissaris een co...
Construction contract in Latvia (solar panel power plant in Vārme pari...
Construction contract in Latvia (solar panel power plant in Vārme parish) On 18 April 2024, PS MB.MEE, part of AS Merko Ehitus group, and SIA SP Venta, which sole shareholder and financier of the project development is UAB Ignitis renewables, entered into a contract to for the construction of solar panel power plant located in Vārme parish, Kuldīga district, Latvia.The works include installation of solar panels with total capacity of 93.5 MW DC, 18 medium-voltage power stations, 232 combiner boxes, irradiance sensors, weather stations, construction of access roads, drainage systems, constru...
Ehitusleping Lätis (päikeseelektripark Vārme vallas)
Ehitusleping Lätis (päikeseelektripark Vārme vallas) 18. aprillil 2024 sõlmisid AS Merko Ehitus kontserni kuuluv PS MB.MEE ja SIA SP Venta, mille ainuomanik ja projektifinantseerija on UAB Ignitis Renewables, lepingu päikeseelektripargi ehitamiseks Lätis, Kuldīga maakonnas, Vārme vallas.Tööd hõlmavad päikesepaneelide, alalisvoolu koguvõimsusega 93,5 MW, 18 keskpinge alajaama, 232 ühenduskilbi, kiirgusandurite ja ilmajaama paigaldamist ning juurdepääsuteede, drenaažisüsteemide ehitamist, keskpingekaabelduse ehitamist ja ühendamist, päikeseelektrijaama katsetamist ja kasutuselevõttu. ...
Annual report 2023 + general shareholders meeting
Annual report 2023 + general shareholders meeting We are delighted and proud to present the annual report of Unifiedpost for the year 2023. You can find the report on the investor relations website of the Company, together with the information about our general shareholders meeting of 2024 via this .
- ABGSC Capital Goods Research
- Karl Bokvist
- Felix Fischer
Lucror Analytics - Morning Views Europe
Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar. To request full and unrestricted access to Lucror’s research and analytics platform, please visit
- ABGSC Capital Goods Research
- Karl Bokvist
- ABGSC Capital Goods Research
- Karl Bokvist
- Olof Cederholm
- ABGSC Capital Goods Research
- Karl Bokvist
Pyramisa Hotels: 2 directors
Two Directors at Pyramisa Hotels sold/bought 18,000 shares at 0.000EGP. The significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Comet bestätigt Prognose trotz des erwartet langsamen Starts ins Gesch...
Comet Holding AG / Schlagwort(e): Quartals-/Zwischenmitteilung Comet bestätigt Prognose trotz des erwartet langsamen Starts ins Geschäftsjahr 19.04.2024 / 06:30 CET/CEST Trading Update 1. Quartal 2024 Nettoumsatz von CHF 80.9 Mio. im Q1/24 (Q1/23: CHF 107.5 Mio.) Book-to-Bill von 1.09 zum Ende von Q1/24 Prognose für das Gesamtjahr 2024 bestätigt Der Nettoumsatz der Comet Group belief sich im Q1/24 auf CHF 80.9 Mio., was einem Rückgang von 24.8% gegenüber dem Vorjahreszeitraum (Q1/23: CHF 107.5 Mio.) und 28.2% gegenüber dem Vorquartal (Q4/23: CHF 112.7 Mio.) entspricht. Di...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.